Get the Stockscreener App
1.86
1.59%
-0.03
After Hours:
1.89
0.03
+1.61%
Genprex Inc stock is traded at $1.86, with a volume of 148.87K.
It is down -1.59% in the last 24 hours and down -33.57% over the past month.
Genprex Inc is a clinical-stage gene therapy company focused on developing life-changing therapies for patients with cancer and diabetes. Its technologies are designed to administer disease-fighting genes to provide new therapies for large patient populations with cancer and diabetes who currently have limited treatment options. Genprex's oncology program utilizes its systemic, non-viral Oncoprex Delivery System which encapsulates the gene-expressing plasmids using lipid-based nanoparticles in a lipoplex form. The company's product candidate, Reqorsa Immunogene Therapy (quaratusugene ozeplasmid), is being evaluated in three clinical trials as a treatment for NSCLC and SCLC.
See More
Previous Close:
$1.89
Open:
$1.87
24h Volume:
148.87K
Relative Volume:
0.22
Market Cap:
$4.22M
Revenue:
-
Net Income/Loss:
$-22.71M
P/E Ratio:
-0.1588
EPS:
-11.71
Net Cash Flow:
$-18.24M
1W Performance:
-19.83%
1M Performance:
-33.57%
6M Performance:
-85.12%
1Y Performance:
-95.99%
1-Day Range:
$1.81
$1.915
1-Week Range:
$1.81
$2.393
52-Week Range:
$1.81
$55.00
Genprex Inc Stock (GNPX) Company Profile
Name
Genprex Inc
Sector
Industry
Phone
512-537-7997
Address
1601 TRINITY STREET, BLDG. B, AUSTIN, TX
Compare GNPX with other stocks
| Stocks | Price | Market Cap | Revenue | Net Income | Cash Flow | EPS |
|---|---|---|---|---|---|---|
GNPX
Genprex Inc
|
1.86 | 4.29M | 0 | -22.71M | -18.24M | -11.71 |
|
VRTX
Vertex Pharmaceuticals Inc
|
462.99 | 116.51B | 11.74B | 3.68B | 3.34B | 14.19 |
|
REGN
Regeneron Pharmaceuticals Inc
|
783.71 | 82.52B | 14.25B | 4.58B | 3.88B | 41.77 |
|
ALNY
Alnylam Pharmaceuticals Inc
|
400.69 | 52.67B | 3.21B | 43.57M | 221.36M | 0.2405 |
|
ARGX
Argen X Se Adr
|
849.95 | 52.08B | 3.06B | 1.28B | 447.35M | 19.67 |
|
INSM
Insmed Inc
|
177.42 | 37.70B | 447.02M | -1.18B | -906.14M | -6.1812 |
Genprex Inc Stock (GNPX) Upgrades & Downgrades
| Date | Action | Analyst | Rating Change |
|---|---|---|---|
| Jan-26-21 | Initiated | National Securities | Buy |
| Apr-29-19 | Initiated | Noble Capital Markets | Outperform |
Genprex Inc Stock (GNPX) Latest News
Genprex reports potential compliance with Nasdaq equity listing rule By Investing.com - Investing.com Canada
Genprex (GNPX) awards 28,500 RSUs to Chief Medical Officer under 2018 plan - Stock Titan
Genprex (GNPX) CEO Ryan Confer reports 45,000 RSUs award - Stock Titan
Genprex (GNPX) grants director 9,000 RSUs after reverse stock split - Stock Titan
Genprex reports potential compliance with Nasdaq equity listing rule - Investing.com
Genprex (GNPX) Stock Analysis Report | Financials & Insights - Benzinga
Street Watch: Will Genprex Inc stock split attract more investorsMarket Trend Review & Real-Time Stock Movement Alerts - moha.gov.vn
How Genprex Inc. stock reacts to inflationary pressuresWeekly Gains Summary & Safe Entry Momentum Stock Tips - Bölüm Sonu Canavarı
MSN Money - MSN
Aug Catalysts: How Genprex Inc. stock reacts to inflationary pressuresQuarterly Profit Review & Verified Chart Pattern Signals - moha.gov.vn
Can Genprex Inc. stock beat market expectations this quarterJuly 2025 Price Swings & Consistent Income Trade Recommendations - Улправда
What catalysts could drive Genprex Inc. stock higherJuly 2025 Setups & Long-Term Capital Growth Strategies - Улправда
How Genprex Inc. stock performs in high volatility marketsInflation Watch & Free Real-Time Market Sentiment Alerts - Улправда
Momentum Shift: Why Genprex Inc stock remains on buy listsEarnings Risk Summary & Fast Moving Stock Watchlists - moha.gov.vn
Will Genprex Inc. (2DE0) stock benefit from mergers2025 Performance Recap & Long-Term Investment Growth Plans - Улправда
12 Health Care Stocks Moving In Friday's After-Market Session - Benzinga
Dividend Watch: Can Genprex Inc. stock beat market expectations this quarterPortfolio Update Report & Technical Confirmation Trade Alerts - Улправда
Why analysts upgrade Genprex Inc. stock2025 Buyback Activity & Fast Moving Stock Watchlists - DonanımHaber
Will Genprex Inc. stock sustain high P E ratios2025 Breakouts & Breakdowns & AI Enhanced Trading Alerts - DonanımHaber
How Genprex Inc. (2DE0) stock reacts to new regulationsQuarterly Portfolio Report & AI Based Trade Execution Alerts - Улправда
Why Genprex Inc. stock is rated strong buyJuly 2025 Final Week & Community Consensus Trade Signals - DonanımHaber
Is Genprex Inc. stock a smart buy before Fed meetingQuarterly Profit Report & Accurate Buy Signal Notifications - DonanımHaber
Genprex Secures U.S. Patent for Reqorsa® Therapy - MSN
Genprex Inc Stock Analysis and ForecastSector-Based Investing & High Yield Market Growth - earlytimes.in
Will Genprex Inc. (2DE0) stock recover faster than industry2025 Analyst Calls & Risk Managed Investment Signals - Newser
Is Genprex Inc. (2DE0) stock undervalued after correctionJuly 2025 PreEarnings & Risk Controlled Daily Trade Plans - Newser
Is Genprex Inc. stock cheap at current valuationWeekly Profit Report & Community Driven Trade Alerts - Newser
Congressman Buys Shares Of Small Cap Lift Truck Company You've Probably Never Heard Of - Benzinga
Can Genprex Inc. (2DE0) stock reach $200 price targetEarnings Growth Summary & Entry and Exit Point Strategies - Newser
Get in on Genprex Inc’s (GNPX) buy-in window today! - setenews.com
Rep. Tim Moore Purchases Shares of Genprex (NASDAQ:GNPX) - Defense World
Why Genprex Inc. stock remains on buy listsWeekly Profit Summary & Fast Gaining Stock Reports - Newser
Genprex, Inc. Stock (GNPX) Opinions on Recent Preclinical Data Release - Quiver Quantitative
Genprex Announces Registered Direct Offering of up to $8.1 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Announces Registered Direct Offering of up to $10.0 Million Priced At-The-Market Under Nasdaq Rules - Aktiellt
Genprex Collaborators to Present Positive Preclinical Data on the Use of Reqorsa® Gene Therapy for the Treatment of Lung Cancer at the 2025 AACR-NCI-EROTC International Conference on Molecular Targets and Cancer Therapeutics (PR Newswire) - Aktiellt
Taking the lead: Genprex Inc (GNPX) - Setenews
Genprex regains Nasdaq bid price compliance, receives equity extension By Investing.com - Investing.com Australia
Genprex regains Nasdaq bid price compliance, receives equity extension - Investing.com
Genprex keeps Nasdaq listing with bid-price fix, equity waiver granted - Stock Titan
Genprex reports phase 1 data for lung cancer gene therapy By Investing.com - Investing.com Nigeria
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Tria - GuruFocus
Genprex (GNPX) Shares Positive Acclaim-1 Trial Data for Lung Can - GuruFocus
Genprex reports phase 1 data for lung cancer gene therapy - Investing.com
Data from Genprex's Acclaim-1 Phase 1 Gene Therapy Clinical Trial Published in Clinical Lung Cancer - PR Newswire
Genprex files prospectus supplement for up to $75 million at-the-market offering By Investing.com - Investing.com Australia
Genprex files prospectus supplement for up to $75 million at-the-market offering - Investing.com Australia
Genprex Inc. (GNPX) Stock Price | Live Quotes & Charts | NASDAQ - StocksToTrade
Genprex Announces $75 Million Stock Offering - MSN
Genprex Inc Stock (GNPX) Financials Data
Revenue
Net Income
Cash Flow
EPS
0.36%
0.21%
Open in Yahoo
|
Open in Google
|
Open in Finviz
|
Open in MarketWatch
|
Open in EDGAR
|
Open in Reuters
Cap:
|
Volume (24h):